VPC12249 | CAS#403520-23-0 | Lysophosphatidic Acid Receptor Type 1 Antagonist

MedKoo Cat#: 532880 | Name: VPC12249

Description:

WARNING: This product is for research use only, not for human or veterinary use.

VPC12249 is a lysophosphatidic acid receptor type 1 (LPA1) antagonist that plays a functional role in osteoclast differentiation and bone resorption activity.

Chemical Structure

VPC12249

CAS#403520-23-0

Theoretical Analysis

MedKoo Cat#: 532880

Name: VPC12249

CAS#: 403520-23-0

Chemical Formula: C34H52NO6P

Exact Mass: 601.3532

Molecular Weight: 601.76

Elemental Analysis: C, 67.86; H, 8.71; N, 2.33; O, 15.95; P, 5.15

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

VPC12249, VPC 12249, VPC-12249

IUPAC/Chemical Name

[(2R)-2-[[(Z)-octadec-9-enoyl]amino]-3-[4-(phenylmethoxy)phenyl]propyl] dihydrogen phosphate

InChi Key

NJLPYJKKKSBCSK-MJPIYRIWSA-N

InChi Code

InChI=1S/C34H52NO6P/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19-22-34(36)35-32(29-41-42(37,38)39)27-30-23-25-33(26-24-30)40-28-31-20-17-16-18-21-31/h9-10,16-18,20-21,23-26,32H,2-8,11-15,19,22,27-29H2,1H3,(H,35,36)(H2,37,38,39)/b10-9-/t32-/m1/s1

SMILES Code

O=P(O)(OC[C@H](NC(CCCCCCC/C=C\CCCCCCCC)=O)CC1=CC=C(OCC2=CC=CC=C2)C=C1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 601.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: David M, Machuca-Gayet I, Kikuta J, Ottewell P, Mima F, Leblanc R, Bonnelye E, Ribeiro J, Holen I, Lopez Vales R, Jurdic P, Chun J, Clézardin P, Ishii M, Peyruchaud O. Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. J Biol Chem. 2014 Mar 7;289(10):6551-64. doi: 10.1074/jbc.M113.533232. Epub 2014 Jan 15. PubMed PMID: 24429286; PubMed Central PMCID: PMC3945319. 2: Gan L, Xue JX, Li X, Liu DS, Ge Y, Ni PY, Deng L, Lu Y, Jiang W. Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation. Biochem Biophys Res Commun. 2011 May 27;409(1):7-13. doi: 10.1016/j.bbrc.2011.04.084. Epub 2011 Apr 23. PubMed PMID: 21545790. 3: Xue J, Gan L, Li X, Li J, Qi G, Wu Y, Fu X, Mao Q, Ao R, Lang J, Lu Y. Effects of lysophosphatidic acid and its receptors LPA⅓ on radiation pneumonitis. Oncol Rep. 2010 Dec;24(6):1515-20. PubMed PMID: 21042747. 4: Xu YJ, Tappia PS, Goyal RK, Dhalla NS. Mechanisms of the lysophosphatidic acid-induced increase in [Ca(2+)](i) in skeletal muscle cells. J Cell Mol Med. 2008 Jun;12(3):942-54. doi: 10.1111/j.1582-4934.2008.00139.x. PubMed PMID: 18494935; PubMed Central PMCID: PMC4401138. 5: Heasley BH, Jarosz R, Lynch KR, Macdonald TL. Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40. PubMed PMID: 15125924. 6: Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T, Kuwabara A, Yanagita Y, Ikeya T, Tanahashi Y, Ogawa T, Ohwada S, Morishita Y, Ohta H, Im DS, Tamoto K, Tomura H, Okajima F. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem. 2004 Feb 20;279(8):6595-605. Epub 2003 Dec 3. PubMed PMID: 14660630. 7: Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem. 2003 Apr 4;278(14):11962-9. Epub 2003 Jan 27. PubMed PMID: 12554733. 8: Heise CE, Santos WL, Schreihofer AM, Heasley BH, Mukhin YV, Macdonald TL, Lynch KR. Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol. 2001 Dec;60(6):1173-80. PubMed PMID: 11723223.